B-cell-targeted therapy for systemic lupus erythematosus: An update

BioDrugs

Volumn 22, Issue 4, 2008, Pages 239-249

  Ding, Changhai ^a   Foote, Simon ^a   Jones, Graeme ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Belimumab, therapeutic use; Epratuzumab, therapeutic use; Research and development; Rituximab, therapeutic use; Systemic lupus erythematosus, treatment

Indexed keywords

ABATACEPT; ANTIMALARIAL AGENT; ATACICEPT; AUTOANTIBODY; B CELL ACTIVATING FACTOR; BELIMUMAB; CD19 ANTIBODY; CD20 ANTIGEN; CD40 LIGAND; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPRATUZUMAB; GLUCOCORTICOID; HYBRID PROTEIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; OCRELIZUMAB; PLACEBO; PREDNISOLONE; RITUXIMAB; STEROID;

ANTIBODY PRODUCTION; B CELL LYMPHOMA; B LYMPHOCYTE; BACTERIAL MENINGITIS; BLOOD TOXICITY; BRADYCARDIA; CELL MATURATION; CELL SURVIVAL; CHICKENPOX; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DECUBITUS; DISEASE ACTIVITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENTERITIS; FEBRILE NEUTROPENIA; FEVER; GRAND MAL SEIZURE; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTIOUS COMPLICATION; INJECTION SITE REACTION; LOBAR PNEUMONIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHOTOSENSITIVITY; PLEURISY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEPTICEMIA; SERUM SICKNESS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URTICARIA;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 47049117913     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822040-00003     Document Type: Review

References (79)

1. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56 (7): 481-90
2. Vila LM, Alarcon GS, McGwin G, et al. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum 2006; 55 (5): 799-806
3. Arce E, Jackson DG, Gill MA, et al. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001; 167 (4): 2361-9
4. Klinman DM, Shirai A, Ishigatsubo Y, et al. Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus. Arthritis Rheum 1991; 34 (11): 1404-10
5. Linker-Israeli M, Deans RJ, Wallace DJ, et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol 1991; 147 (1): 117-23
6. Ding C, Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr Opin Investig Drugs 2006; 7 (5): 464-72
7. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48 (12): 3475-86
8. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006; 24: 467-96
9. Grammer AC, Lipsky PE. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 2003; 5 Suppl. 4: S22-7
10. Boumpas DT, Austin III HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340 (8822): 741-5
11. Stohl W, Looney RJ. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin Immunol 2006 Oct; 121 (1): 1-12
12. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20: "what do B-cells do?" Clin Immunol 2005; 117 (3): 207-13
13. Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006; 2 (1): 20-7
14. Lajaunias F, Ida A, Kikuchi S, et al. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus. Arthritis Rheum 2003; 48 (6): 1612-21
15. Otipoby KL, Andersson KB, Draves KE, et al. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 1996; 384 (6610): 634-7
16. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6 (5): 394-403
17. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20 (6): 785-98
18. Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006; 66 (15): 1933-48
19. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003; 48 (6): 1484-92
20. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006; 5 (7): 564-76
21. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83 (2): 435-45
22. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174 (2): 817-26
23. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease: the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007; 3 (2): 86-95
24. Clark EA, Ledbetter JA. How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis 2005; 64 Suppl. 4: iv77-80
25. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48 (2): 455-9
26. Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B-cell depletion in SLE. Ann Rheum Dis. Epub 2008 Feb 4
27. Galarza C, Valencia D, Tobón GJ, et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 2008; 34 (1): 124-8
28. Lindholm C, Börjesson-Asp K, Zendjanchi K, et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008; 35 (5): 826-33
29. Tamimoto Y, Horiuchi T, Tsukamoto H, et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology (Oxford) 2008; 47 (6): 821-7
30. Nwobi O, Abitbol CL, Chandar J, et al. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 2008; 23 (3): 413-9
31. Podolskaya A, Stadermann M, Pilkington C, et al. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 2008; 93 (5): 401-6
32. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50 (11): 3580-90
33. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50 (8): 2580-9
34. Anolik JH, Barnard J, Looney RJ, et al. Long-term effects of rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2005; 52 (9): S190
35. Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44 (12): 1542-5
36. Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007; 66 (9): 1259-62
37. Ng KP, Leandro MJ, Edwards JC, et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006; 65 (7): 942-5
38. Smith KG, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006; 54 (9): 2970-82
39. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52 (2): 501-13
40. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8 (3): R83
41. Gunnarsson I, Sundelin B, Jonsdottir T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide- resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56 (4): 1263-72
42. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66 (4): 470-5
43. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52 (10): 3168-74
44. Levy D, Adams B, Kahn P, et al. Rituximab in treatment-resistant childhood-onset systemic lupus erythematosus [abstract]. Arthritis Rheum 2005; 52 (9): S531
45. Willems M, Haddad E, Niaudet P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006; 148 (5): 623-7
46. Cruz MC, Onel KB, Wagner-Weiner L, et al. Rituximab therapy in pediatric systemic lupus erythematosus: long-term followup [abstract]. Arthritis Rheum 2006; 54 (12): 4054
47. Barillas-Arias L, Adams AB, Angeles ST, et al. Combination of rituximab and cyclophosphamide for the treatment of childhood onset systemic lupus erythematosus [abstract]. Arthritis Rheum 2006; 54 (9): S689-90
48. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350 (25): 2572-81
49. Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54 (11): 3612-22
50. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46 (10): 2673-7
51. Albert D, Khan S, Stansberry J, et al. A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus [abstract]. Arthritis Rheum 2004; 50 (9): S446
52. Dunham J, Prak NL, Du YZ, et al. A longitudinal analysis of SLE patients treated with rituximab: a comparison of B cell depleters to partial B cell depleters [abstract]. Arthritis Rheum 2005; 52 (9): S740
53. Tokunaga M, Fujii K, Saito K, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 2005; 44 (2): 176-82
54. Sfikakis PP, Souliotis VL, Fragiadaki KG, et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007; 123 (1): 66-73
55. van Vollenhoven R, Gunnarsson I, Welin-Henriksson E, et al. Rituximab plus cyclophosphamide in severe SLE: results in 15 patients who failed conventional immunosuppressive therapy [abstract]. Arthritis Rheum 2005; 52 (9): S741
56. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007; 122 (1): 62-74
57. Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17 (3): 191-7
58. Gillis JZ, Dall'era M, Gross A, et al. Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 2007; 57 (3): 538-42
59. Guzman RA, Garcia O. Rituximab and mycophenolate mofetil: induction treatment and management of severe lupus nephritis [abstract]. Ann Rheum Dis 2007; 66 Suppl. II: 306
60. Roccatello D, Rossi D, Mirella A, et al. Rituximab as a therapeutic option in severe systemic lupus erythematosus [abstract]. Ann Rheum Dis 2007; 66 Suppl. II: 479
61. Hernandez MC, Olguin L, Saavedra MA, et al. Rituximab for refractory hematological manifestations of systemic lupus erythematosus and antiphospholipid syndrome [abstract]. Ann Rheum Dis. 2007; 66 Suppl. II: 465
62. Jonsdottir T, Gunnarsson I, Risselada AP, et al. Major clinical responses in severe SLE following treatment with rituximab plus cyclophosphamide are predicted by lower baseline CD19 lymphocyte count and greater changes in IgA anti-DNA [abstract]. Arthritis Rheum 2006; 54 (9): S790-1
63. US FDA. FDA warns of safety concern regarding Rituxan in new patient population [media release; online]. Rockville (MD): FDA, 2006 Dec 18. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01532.html. [Accessed 2008 Jun 4]
64. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16 (8): 2825-33
65. Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003; 9 (10 Pt 2): S3982-90
66. Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007 Feb; 44 (6): 1331-41
67. Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8 (3): R74
68. Jacobi AM, Goldenberg DM, Hiepe FT, et al. Differential effects of epratuzumab on peripheral blood B cells of SLE patients versus normal controls. Ann Rheum Dis 2008; 67 (4): 450-7
69. Wallace DJ, Lisse J, Stohl W, et al. Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks [abstract]. Arthritis Rheum 2006; 54 (9): S790
70. Furie R, Lisse J, Merrill JT, et al. Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLyS]) improves or stabilizes SLE activity in a multicenter phase 2 trial [abstract]. Arthritis Rheum 2006; 54 (9): S258
71. Stohl W, Wallace DJ, Merrill JT, et al. Changes in circulating B-cell counts, autoantibody levels and immunoglobulins that associate with therapeutic responsiveness in SLE to BLyS protein antagonism by belimumab [abstract]. Arthritis Rheum 2006; 54 (9): S780
72. Strand V, Crawford B, Petri M, et al. Patients with active systemic lupus erythematosus (SLE) treated with belimumab improve health-related quality of life (HRQOL) in a randomized controlled trial (RCT) [abstract]. Arthritis Rheum 2006; 54 (9): S277-8
73. Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007; 66 (5): 700-3
74. Vallerskog T, Heimburger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006; 8 (6): R167
75. Genovese MC, Kaine JL, Kohen MD, et al. Safety and clinical activity of ocrelizumab (a humanized antibody targeting C D20+ B cells) in combination with methotrexate (MTX) in moderate-severe rheumatoid arthritis (RA) patients (pts) (Ph I/II ACTION study) [abstract]. Arthritis Rheum 2006; 54 (9): S66-7
76. Østergaard M, Baslund B, Rigby W, et al. Ofatumumab (humax-CD20), a fully human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis: early results from an ongoing, double-blind, randomized, placebo controlled clinical trial [abstract]. Ann Rheum Dis 2007; 66 Suppl. II: 124
77. Burge DJ, Shu C, Martin RW, et al. TRU-015, a small modular immunopharmaceutical (SMIPTM) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis [abstract]. Arthritis Rheum 2006; 54 (9): S230
78. Dall'era M, Chakravarty E, Genovese M, et al. Trial of atacicept in patients with systemic lupus erythematosus (SLE) [abstract]. Arthritis Rheum 2006; 54 (12): 4042-3
79. Liossis SN, Sfikakis PP. Costimulation blockade in the treatment of rheumatic diseases. BioDrugs 2004; 18 (2): 95-102